Continuous biomanufacturing in upstream and downstream processing

References

1. Fisher, AC, Lee, SL, Harris, DP, Buhse, L, Kozlowski, S, Yu, L, et al.. Advancing pharmaceutical quality: an overview of science and research in the U.S. FDA’s Office of Pharmaceutical Quality. Int J Pharm 2016;515:390–402. https://doi.org/10.1016/j.ijpharm.2016.10.038.Search in Google Scholar PubMed

2. Fisher, AC, Liu, W, Schick, A, Ramanadham, M, Chatterjee, S, Brykman, R, et al.. An audit of pharmaceutical continuous manufacturing regulatory submissions and outcomes in the US. Int J Pharm 2022;622:121778. https://doi.org/10.1016/j.ijpharm.2022.121778.Search in Google Scholar PubMed

3. Lee, SL, O’Connor, TF, Yang, X, Cruz, CN, Chatterjee, S, Madurawe, RD, et al.. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov 2015;10:191–9. https://doi.org/10.1007/s12247-015-9215-8.Search in Google Scholar

4. ISPE | International Society for Pharmaceutical Engineering. Continuous manufacturing as a tool for accelerated development. https://ispe.org/pharmaceutical-engineering/july-august-2021/continuous-manufacturing-tool-accelerated-development [Accessed 19 Apr 2023].Search in Google Scholar

5. Jarrett, S, Pagliusi, S, Park, R, Wilmansyah, T, Jadhav, S, Santana, PC, et al.. The importance of vaccine stockpiling to respond to epidemics and remediate global supply shortages affecting immunization: strategic challenges and risks identified by manufacturers. Vaccine X 2021;9:100119. https://doi.org/10.1016/j.jvacx.2021.100119.Search in Google Scholar PubMed PubMed Central

6. Zhu, G, Chou, MC, Tsai, CW. Lessons learned from the COVID-19 pandemic exposing the shortcomings of current supply chain operations: a long-term prescriptive offering. Sustainability 2020;12:5858. https://doi.org/10.3390/su12145858.Search in Google Scholar

7. Kleinebudde, P, Khinast, J, Rantanen, J. Continuous manufacturing of pharmaceuticals, 1st. Hoboken, New Jersey: John Wiley & Sons; 2017.10.1002/9781119001348Search in Google Scholar

8. Konstantinov, KB, Cooney, CL. White paper on continuous bioprocessing May 20–21 2014 continuous manufacturing symposium. J Pharmaceut Sci 2015;104:813–20. https://doi.org/10.1002/jps.24268.Search in Google Scholar PubMed

9. Woodcock, J. Modernizing pharmaceutical manufacturing–continuous manufacturing as a key enabler. In: Proceedings of the MIT-CMAC International symposium on continuous manufacturing of pharmaceuticals. Cambridge, MA, USA; 2014, 20.Search in Google Scholar

10. Hengelbrock, A, Schmidt, A, Helgers, H, Vetter, FL, Strube, J. Scalable mRNA machine for regulatory approval of variable scale between 1000 clinical doses to 10 million manufacturing scale doses. Processes 2023;11:745. https://doi.org/10.3390/pr11030745.Search in Google Scholar

11. Croughan, MS, Konstantinov, KB, Cooney, C. The future of industrial bioprocessing: batch or continuous? Biotechnol Bioeng 2015;112:648–51. https://doi.org/10.1002/bit.25529.Search in Google Scholar PubMed

12. Ding, B. Pharma Industry 4.0: literature review and research opportunities in sustainable pharmaceutical supply chains. Process Saf Environ Protect 2018;119:115–30. https://doi.org/10.1016/j.psep.2018.06.031.Search in Google Scholar

13. Yu, YB, Briggs, KT, Taraban, MB, Brinson, RG, Marino, JP. Grand challenges in pharmaceutical research series: ridding the cold chain for biologics. Pharm Res 2021;38:3–7. https://doi.org/10.1007/s11095-021-03008-w.Search in Google Scholar PubMed PubMed Central

14. Ghani, S. ICH quality guidelines. In: Chan, CC, Chow, K, Mckay, B, Fung, M, editors. Therapeutic delivery solutions. Hoboken, New Jersey: John Wiley & Sons; 2014:367–80 pp.10.1002/9781118903681.ch13Search in Google Scholar

15. Teasdale, A, Elder, D, Nims, RW. ICH quality guidelines: an implementation guide. In: Teasdale, A, Elder, D, Nims, RW, editors, 1st ed. Hoboken, New Jersey: John Wiley & Sons; 2017.10.1002/9781118971147Search in Google Scholar

16. Kornecki, M, Schmidt, A, Strube, J. PAT as key-enabling technology for QbD in pharmaceutical manufacturing a conceptual review on upstream and downstream processing. Chimica Oggi Chem Today 2018;36:44–8.Search in Google Scholar

17. Godawat, R, Konstantinov, K, Rohani, M, Warikoo, V. End-to-end integrated fully continuous production of recombinant monoclonal antibodies. J Biotechnol 2015;213:13–19. https://doi.org/10.1016/j.jbiotec.2015.06.393.Search in Google Scholar PubMed

18. FDA’s comprehensive effort to advance new innovations: initiatives to modernize for innovation. FDA [Online], Thu, March 10, 2022 – 10:09. https://www.fda.gov/news-events/fda-voices/fdas-comprehensive-effort-advance-new-innovations-initiatives-modernize-innovation [Accessed 19 Apr 2023].Search in Google Scholar

19. FDA’s new efforts to advance biotechnology innovation. FDA [Online], Thu, March 10, 2022 – 12:16. https://www.fda.gov/news-events/fda-voices/fdas-new-efforts-advance-biotechnology-innovation [Accessed 19 Apr 2023].Search in Google Scholar

20. Udugama, IA, Lopez, PC, Gargalo, CL, Li, X, Bayer, C, Gernaey, KV. Digital Twin in biomanufacturing: challenges and opportunities towards its implementation. Syst Microbiol Biomanuf 2021;1:257–74. https://doi.org/10.1007/s43393-021-00024-0.Search in Google Scholar

21. Subramanian, G., editor. Process control, intensification, and digitalisation in continuous biomanufacturing. Weinheim: Wiley-VCH; 2022.10.1002/9783527827343Search in Google Scholar

22. Khanal, O, Lenhoff, AM. Developments and opportunities in continuous biopharmaceutical manufacturing. mAbs 2021;13:1903664. https://doi.org/10.1080/19420862.2021.1903664.Search in Google Scholar PubMed PubMed Central

23. Boodhoo, K, Flickinger, MC, Woodley, JM, Emanuelsson, E. Bioprocess intensification: a route to efficient and sustainable biocatalytic transformations for the future. Chem Eng Process Process Intensif 2022;172:108793. https://doi.org/10.1016/j.cep.2022.108793.Search in Google Scholar

24. Mahmoud, MS, Sabih, M, Elshafei, M. Using OPC technology to support the study of advanced process control. ISA Trans 2015;55:155–67. https://doi.org/10.1016/j.isatra.2014.07.013.Search in Google Scholar PubMed

25. Shao, G, Latif, H, Martin-Villalba, C, Denno, P. Standards-based integration of advanced process control and optimization. J Ind Inf Integr 2019;13:1–12. https://doi.org/10.1016/j.jii.2018.10.001.Search in Google Scholar PubMed PubMed Central

26. European Pharmaceutical Review. Key challenges for bio/pharmaceutical manufacturing 2022. https://www.europeanpharmaceuticalreview.com/article/167733/key-challenges-for-bio-pharmaceutical-manufacturing-2022/ [Accessed 19 Apr 2023].Search in Google Scholar

27. ISPE | International Society for Pharmaceutical Engineering. Data science for pharma 4.0™, drug development, & production—Part 1. https://ispe.org/pharmaceutical-engineering/march-april-2021/data-science-pharma-40tm-drug-development-production [Accessed 19 Apr 2023].Search in Google Scholar

28. Otto, Ralf, et al.. Rapid growth in biopharma: challenges and opportunities. McKinsey & Company; 2014;1.Search in Google Scholar

29. Erickson, J, Baker, J, Barrett, S, Brady, C, Brower, M, Carbonell, R, et al.. End-to-end collaboration to transform biopharmaceutical development and manufacturing. Biotechnol Bioeng 2021;118:3302–12. https://doi.org/10.1002/bit.27688.Search in Google Scholar PubMed PubMed Central

30. Mathur, AK, Vyas, A. Greening of management: social responsibility of Indian pharmaceutical industry. Int J Pharm Sci Res 2013;4:502–5.Search in Google Scholar

31. Schmidt, A, Uhlenbrock, L, Strube, J. Technical potential for energy and GWP reduction in chemical–pharmaceutical industry in Germany and EU—focused on biologics and botanicals manufacturing. Processes 2020;8:818. https://doi.org/10.3390/pr8070818.Search in Google Scholar

32. Madabhushi, SR, Pinto, NDS, Lin, H. Comparison of process mass intensity (PMI) of continuous and batch manufacturing processes for biologics. Nat Biotechnol 2022;72:122–7. https://doi.org/10.1016/j.nbt.2022.11.002.Search in Google Scholar PubMed

33. Kumar, A, Udugama, IA, Gargalo, CL, Gernaey, KV. Why is batch processing still dominating the biologics landscape? Towards an integrated continuous bioprocessing alternative. Processes 2020;8:1641. https://doi.org/10.3390/pr8121641.Search in Google Scholar

34. Boedeker, GD. “Recombinant factor VIII (Kogenate®) for the treatment of hemophilia a: the first and only World‐Wide licensed recombinant protein produced in high‐throughput perfusion culture.” In: Modern biopharmaceuticals: recent success stories. Weinheim Wiley-VCH; 2013: 429–43 pp.10.1002/9783527669417.ch19Search in Google Scholar

35. Schmidt, A, Helgers, H, Vetter, FL, Juckers, A, Strube, J. Digital twin of mRNA-based SARS-COVID-19 vaccine manufacturing towards autonomous operation for improvements in speed, scale, robustness, flexibility and real-time release testing. Processes 2021;9:748. https://doi.org/10.3390/pr9050748.Search in Google Scholar

36. Reinhardt, IC, Oliveira, JC, Ring, DT. Current perspectives on the development of industry 4.0 in the pharmaceutical sector. J Ind Inf Integr 2020;18:100131. https://doi.org/10.1016/j.jii.2020.100131.Search in Google Scholar

37. Chen, Y, Yang, O, Sampat, C, Bhalode, P, Ramachandran, R, Ierapetritou, M. Digital twins in pharmaceutical and biopharmaceutical manufacturing: a literature review. Processes 2020;8:1088. https://doi.org/10.3390/pr8091088.Search in Google Scholar

38. Rao, V, Srinivas, K. Modern drug discovery process. An in silico approach J Bioinform Sequence Anal 2011;2:89–94.Search in Google Scholar

39. Erol, T, Mendi, AF, Dogan, D. The digital twin revolution in Healthcare. In: 2020 4th International Symposium on Multidisciplinary Studies and Innovative Technologies (ISMSIT), Istanbul, Turkey, 22–24 Oct. 2020. IEEE; 2020:1–7 pp.10.1109/ISMSIT50672.2020.9255249Search in Google Scholar

40. Coorey, G, Figtree, GA, Fletcher, DF, Redfern, J. The health digital twin: advancing precision cardiovascular medicine. Nat Rev Cardiol 2021;18:803–4. https://doi.org/10.1038/s41569-021-00630-4.Search in Google Scholar PubMed

41. Fraunhofer-Gesellschaft. med2icin. https://websites.fraunhofer.de/med2icin/ [Accessed 5 Jan 2023].Search in Google Scholar

42. Venkatesh, KP, Raza, MM, Kvedar, JC. Health digital twins as tools for precision medicine: considerations for computation, implementation, and regulation. NPJ Digit Med 2022;5:150. https://doi.org/10.1038/s41746-022-00694-7.Search in Google Scholar PubMed PubMed Central

43. Valerio, LG. Application of advanced in silico methods for predictive modeling and information integration. Expet Opin Drug Metabol Toxicol 2012;8:395–8. https://doi.org/10.1517/17425255.2012.664636.Search in Google Scholar PubMed

44. Rønning-Andersson, A, Pedersen, DIK. Novo Nordisk and Novartis will participate in large Danish project on decentralized clinical trials. JP/Politikens Hus A/S [Online]. September 28, 2022. https://medwatch.com/News/Pharma___Biotech/article14445325.ece [Accessed 5 Jan 2023].Search in Google Scholar

45. Lorenz, S, Amsel, A-K, Puhlmann, N, Reich, M, Olsson, O, Kümmerer, K. Toward application and implementation of in silico tools and workflows within benign by design approaches. ACS Sustainable Chem Eng 2021;9:12461–75. https://doi.org/10.1021/acssuschemeng.1c03070.Search in Google Scholar

46. Boetker, J, Raijada, D, Aho, J, Khorasani, M, Søgaard, SV, Arnfast, L, et al.. In silico product design of pharmaceuticals. Asian J Pharm Sci 2016;11:492–9. https://doi.org/10.1016/j.ajps.2016.02.010.Search in Google Scholar

47. Roush, D, Asthagiri, D, Babi, DK, Benner, S, Bilodeau, C, Carta, G, et al.. Toward in silico CMC: an industrial collaborative approach to model-based process development. Biotechnol Bioeng 2020;117:3986–4000. https://doi.org/10.1002/bit.27520.Search in Google Scholar PubMed

48. Zobel-Roos, S, Schmidt, A, Uhlenbrock, L, Ditz, R, Köster, D, Strube, J. Digital twins in biomanufacturing. Adv Biochem Eng Biotechnol 2021;176:181–262. https://doi.org/10.1007/10_2020_146.Search in Google Scholar PubMed

49. Klatt, K-U, Marquardt, W. Perspectives for process systems engineering – a personal view from academia and industry. In: 17th European symposium on computer aided process engineering, Elsevier; 2007:19–32 pp.10.1016/S1570-7946(07)80027-7Search in Google Scholar

50. Thon, C, Finke, B, Kwade, A, Schilde, C. Artificial intelligence in process engineering. Adv Intell Syst 2021;3:2000261. https://doi.org/10.1002/aisy.202000261.Search in Google Scholar

51. Mowbray, M, Vallerio, M, Perez-Galvan, C, Zhang, D, Del Rio Chanona, A, Navarro-Brull, FJ. Industrial data science – a review of machine learning applications for chemical and process industries. React Chem Eng 2022;7:1471–509. https://doi.org/10.1039/d1re00541c.Search in Google Scholar

52. SKF. Measuring unscheduled downtime. Paper Advance [Online]. September 2, 2021. https://www.paperadvance.com/mills-technologies/process-optimization/measuring-unscheduled-downtime.html [Accessed 5 Jan 2023].Search in Google Scholar

53. Udugama, IA, Bayer, C, Baroutian, S, Gernaey, KV, Yu, W, Young, BR. Digitalisation in chemical engineering: industrial needs, academic best practice, and curriculum limitations. Educ Chem Eng 2022;39:94–107. https://doi.org/10.1016/j.ece.2022.03.003.Search in Google Scholar

54. Mouellef, M, Vetter, FL, Strube, J. Benefits and limitations of artificial neural networks in process chromatography design and operation. Processes 2023;11:1115. https://doi.org/10.3390/pr11041115.Search in Google Scholar

55. Leng, J, Wang, D, Shen, W, Li, X, Liu, Q, Chen, X. Digital twins-based smart manufacturing system design in Industry 4.0: a review. J Manuf Syst 2021;60:119–37. https://doi.org/10.1016/j.jmsy.2021.05.011.Search in Google Scholar

56. Cimino, C, Negri, E, Fumagalli, L. Review of digital twin applications in manufacturing. Comput Ind 2019;113:103130. https://doi.org/10.1016/j.compind.2019.103130.Search in Google Scholar

57. Gargalo, CL, de Las Heras, SC, Jones, MN, Udugama, I, Mansouri, SS, Krühne, U, et al.. Towards the development of digital twins for the bio-manufacturing industry. Adv Biochem Eng Biotechnol 2021;176:1–34. https://doi.org/10.1007/10_2020_142.Search in Google Scholar PubMed

58. Sixt, M, Uhlenbrock, L, Strube, J. Toward a distinct and quantitative validation method for predictive process modelling—on the example of solid-liquid extraction processes of complex plant extracts. Processes 2018;6:66. https://doi.org/10.3390/pr6060066.Search in Google Scholar

59. Zobel-Roos, S, Schmidt, A, Mestmäcker, F, Mouellef, M, Huter, M, Uhlenbrock, L, et al.. Accelerating biologics manufacturing by modeling or: is approval under the QbD and PAT approaches demanded by authorities acceptable without a digital-twin? Processes 2019;7:94. https://doi.org/10.3390/pr7020094.Search in Google Scholar

60. Uhl, A, Schmidt, A, Hlawitschka, MW, Strube, J. Autonomous liquid–liquid extraction operation in biologics manufacturing with aid of a digital twin including process analytical technology. Processes 2023;11:553. https://doi.org/10.3390/pr11020553.Search in Google Scholar

61. ICH. Technical and regulatory considerations for pharmaceutical product lifecycle management Q12. In: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use; 2017.Search in Google Scholar

62. Reardon, KF. Practical monitoring technologies for cells and substrates in biomanufacturing. Curr Opin Biotechnol 2021;71:225–30. https://doi.org/10.1016/j.copbio.2021.08.006.Search in Google Scholar PubMed

63. Silva, TC, Eppink, M, Ottens, M. Automation and miniaturization: enabling tools for fast, high‐throughput process development in integrated continuous biomanufacturing. J Chem Tech Biotechnol 2022;97:2365–75. https://doi.org/10.1002/jctb.6792.Search in Google Scholar

64. Evaluate Pharmaceutical. World preview 2018, outlook to 2024. Evaluate Ltd. 2018;1–47.Search in Google Scholar

65. Sommerfeld, S, Strube, J. Challenges in biotechnology production – generic processes and process optimization for monoclonal antibodies. Chem Eng Process Process Intensif 2005;44:1123–37. https://doi.org/10.1016/j.cep.2005.03.006.Search in Google Scholar

66. Gronemeyer, P, Ditz, R, Strube, J. Trends in upstream and downstream process development for antibody manufacturing. Bioengineering 2014;1:188–212. https://doi.org/10.3390/bioengineering1040188.Search in Google Scholar PubMed

67. Kelley, B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol Prog 2007;23:995–1008. https://doi.org/10.1021/bp070117s.Search in Google Scholar PubMed

68. Strube, J, Ditz, R, Kornecki, M, Huter, M, Schmidt, A, Thiess, H, et al.. Process intensification in biologics manufacturing. Chem Eng Process Process Intensif 2018;133:278–93. https://doi.org/10.1016/j.cep.2018.09.022.Search in Google Scholar

69. Strube, J, Grote, F, Ditz, R. Bioprocess design and production technology for the future. Biopharmaceutical production technology. Wiley-VCH Verlag GmbH & Co. KGaA; 2012:657–705 pp.10.1002/9783527653096.ch20Search in Google Scholar

70. Singh, N, Arunkumar, A, Chollangi, S, Tan, ZG, Borys, M, Li, ZJ. Clarification technologies for monoclonal antibody manufacturing processes: current state and future perspectives. Biotechnol Bioeng 2016;113:698–716. https://doi.org/10.1002/bit.25810.Search in Google Scholar PubMed

71. Jain, E, Kumar, A. Upstream processes in antibody production: evaluation of critical parameters. Biotechnol Adv 2008;26:46–72. https://doi.org/10.1016/j.biotechadv.2007.09.004.Search in Google Scholar PubMed

72. Pollock, J, Ho, SV, Farid, SS. Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty. Biotechnol Bioeng 2013;110:206–19. https://doi.org/10.1002/bit.24608.Search in Google Scholar PubMed

73. Birch, JR, Racher, AJ. Antibody production. Adv Drug Deliv Rev 2006;58:671–85. https://doi.org/10.1016/j.addr.2005.12.006.Search in Google Scholar PubMed

74. Al-Rubeai, M, editor. Animal cell culture. Cham: Springer International Publishing; 2015.10.1007/978-3-319-10320-4Search in Google Scholar

75. Subramanian, G, editor. Continuous biomanufacturing - innovative technologies and methods. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2017.10.1002/9783527699902Search in Google Scholar

76. Subramanian, G, editor. Biopharmaceutical production technology. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2012.Search in Google Scholar

77. Subramanian, G, editor. Bioseparation and bioprocessing, 2nd ed. Weinheim, Germany: Wiley VCH; 2007.Search in Google Scholar

78. Rita Costa, A, Elisa Rodrigues, M, Henriques, M, Azeredo, J, Oliveira, R. Guidelines to cell engineering for monoclonal antibody production. Eur J Pharm Biopharm 2010;74:127–38. https://doi.org/10.1016/j.ejpb.2009.10.002.Search in Google Scholar PubMed

79. Gstraunthaler, G, Lindl, T. Zell- und Gewebekultur: Allgemeine Grundlagen und spezielle Anwendungen, 7. Auflage. Berlin, Heidelberg, s.l.: Springer Berlin Heidelberg; 2013.10.1007/978-3-642-35997-2Search in Google Scholar

80. Gronemeyer, P, Ditz, R, Strube, J. Implementation of aqueous two-phase extraction combined with precipitation in a monoclonal antibody manufacturing process. Chimica Oggi Chem Today 2016;34:66–70.Search in Google Scholar

81. Gronemeyer, P, Schmidt, A, Zobel, S, Strube, J. Efficient manufacturing of biologics. Chem Ing Tech 2016;88:1329. https://doi.org/10.1002/cite.201650296.Search in Google Scholar

82. Gronemeyer, P, Thiess, H, Zobel-Roos, S, Ditz, R, Strube, J. Integration of upstream and downstream in continuous biomanufacturing. In: Subramanian, G, editor. Continuous biomanufacturing – innovative technologies and methods. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2017:481–510 pp.10.1002/9783527699902.ch17Search in Google Scholar

83. Jungbauer, A. Continuous downstream processing of biopharmaceuticals. Trends Biotechnol 2013;31:479–92. https://doi.org/10.1016/j.tibtech.2013.05.011.Search in Google Scholar PubMed

84. Karst, DJ, Steinebach, F, Soos, M, Morbidelli, M. Process performance and product quality in an integrated continuous antibody production process. Biotechnol Bioeng 2017;114:298–307. https://doi.org/10.1002/bit.26069.Search in Google Scholar PubMed

85. Karst, DJ, Serra, E, Villiger, TK, Soos, M, Morbidelli, M. Characterization and comparison of ATF and TFF in stirred bioreactors for continuous mammalian cell culture processes. Biochem Eng J 2016;110:17–26. https://doi.org/10.1016/j.bej.2016.02.003.Search in Google Scholar

86. Warikoo, V, Godawat, R, Brower, K, Jain, S, Cummings, D, Simons, E, et al.. Integrated continuous production of recombinant therapeutic proteins. Biotechnol Bioeng 2012;109:3018–29. https://doi.org/10.1002/bit.24584.Search in Google Scholar PubMed

87. Zydney, AL. Continuous downstream processing for high value biological products: a review. Biotechnol Bioeng 2016;113:465–75. https://doi.org/10.1002/bit.25695.Search in Google Scholar PubMed

88. Hernandez, R. Continuous manufacturing: a changing processing paradigm. Biopharm Int 2015;2015:20–7.Search in Google Scholar

89. Montgomery, A, Scott, C, Center, A. Continuous Chromatography: experts weigh in on the possibilities and the reality. Boston, MA, USA: BioProcess International; 2019.Search in Google Scholar

90. Thiess, H, Zobel-Roos, S, Gronemeyer, P, Ditz, R, Strube, J. Engineering challenges of continuous biomanufacturing processes (CBP). In: Subramanian, G, editor. Continuous biomanufacturing – innovative technologies and methods. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2017:69–106 pp.10.1002/9783527699902.ch3Search in Google Scholar

91. Steinebach, F, Ulmer, N, Wolf, M, Decker, L, Schneider, V, Walchli, R, et al.. Design and operation of a continuous integrated monoclonal antibody production process. Biotechnol Prog 2017;33:1303–13. https://doi.org/10.1002/btpr.2522.Search in Google Scholar PubMed

92. Kateja, N, Kumar, D, Sethi, S, Rathore, AS. Non-protein A purification platform for continuous processing of monoclonal antibody therapeutics. J Chromatogr A 2018;1579:60–72. https://doi.org/10.1016/j.chroma.2018.10.031.Search in Google Scholar PubMed

93. Whitford, W. GE Healthcare. Continuous biomanufacturing: 10 reasons sponsors Hesitate. https://www.bioprocessonline.com/doc/continuous-biomanufacturing-reason-sponsors-hesitate-0001 [Accessed 16 May 2019].Search in Google Scholar

94. Helgers, H, Schmidt, A, Strube, J. Towards autonomous process control—digital twin for CHO cell-based antibody manufacturing using a dynamic metabolic model. Processes 2022;10:316. https://doi.org/10.3390/pr10020316.Search in Google Scholar

95. Pisano, R, Arsiccio, A, Capozzi, LC, Trout, BL. Achieving continuous manufacturing in lyophilization: technologies and approaches. Eur J Pharm Biopharm 2019;142:265–79. https://doi.org/10.1016/j.ejpb.2019.06.027.Search in Google Scholar PubMed

96. Kornecki, M, Schmidt, A, Lohmann, L, Huter, M, Mestmäcker, F, Klepzig, L, et al.. Accelerating biomanufacturing by modeling of continuous bioprocessing—piloting case study of monoclonal antibody manufacturing. Processes 2019;7:495. https://doi.org/10.3390/pr7080495.Search in Google Scholar

97. Helgers, H, Schmidt, A, Lohmann, LJ, Vetter, FL, Juckers, A, Jensch, C, et al.. Towards autonomous operation by advanced process control—process analytical technology for continuous biologics antibody manufacturing. Processes 2021;9:172. https://doi.org/10.3390/pr9010172.Search in Google Scholar

98. Hammerschmidt, N, Hobiger, S, Jungbauer, A. Continuous polyethylene glycol precipitation of recombinant antibodies: sequential precipitation and resolubilization. Process Biochem 2016;51:325–32. https://doi.org/10.1016/j.procbio.2015.11.032.Search in Google Scholar

99. Burgstaller, D, Jungbauer, A, Satzer, P. Continuous integrated antibody precipitation with two-stage tangential flow microfiltration enables constant mass flow. Biotechnol Bioeng 2019;116:1053–65. https://doi.org/10.1002/bit.26922.Search in Google Scholar PubMed PubMed Central

100. Dutra, G, Komuczki, D, Jungbauer, A, Satzer, P. Continuous capture of recombinant antibodies by ZnCl2 precipitation without polyethylene glycol. Eng Life Sci 2020;20:265–74. https://doi.org/10.1002/elsc.201900160.Search in Google Scholar PubMed PubMed Central

101. Li, Z, Gu, Q, Coffman, JL, Przybycien, T, Zydney, AL. Continuous precipitation for monoclonal antibody capture using countercurrent washing by microfiltration. Biotechnol Prog 2019;35:e2886. https://doi.org/10.1002/btpr.2886.Search in Google Scholar PubMed

102. Lohmann, LJ, Strube, J. Accelerating biologics manufacturing by modeling: process integration of precipitation in mAb downstream processing. Processes 2020;8:58. https://doi.org/10.3390/pr8010058.Search in Google Scholar

103. Lohmann, LJ, Strube, J. Process analytical technology for precipitation process integration into biologics manufacturing towards autonomous operation—mAb case study. Processes 2021;9:488. https://doi.org/10.3390/pr9030488.Search in Google Scholar

104. Lohmann, LJ. Quality by Design basierte Prozessintegration der Präzipitati-on von Monoklonalen Antikörpern sowie die Entwicklung eines Digitalen Zwillings zur Unterstützung der PAT-gestützten autonomen Prozessführung: Shaker Verlag. Clausthal-Zellerfeld: University of Technology Clausthal; 2022.Search in Google Scholar

105. Li, Z. Development of an integrated precipitation-filtration process for initial purification of recombinant proteins - Dissertation. PennState University Libraries; 2020.Search in Google Scholar

106. Schmidt, A, Helgers, H, Lohmann, LJ, Vetter, F, Juckers, A, Mouellef, M, et al.. Process analytical technology as key‐enabler for digital twins in continuous biomanufacturing. J Chem Tech Biotechnol 2022;97:2336–46. https://doi.org/10.1002/jctb.7008.Search in Google Scholar

107. Biologics, S. Large-scale continuous biomanufacturing: utilizing N-1 technology for higher productivity and quality. https://samsungbiologics.com/media/science-technology/large-scale-continuous-biomanufacturing-utilizing-n-1-technology-for-higher-productivity-and-quality [Accessed 19 Apr 2023].Search in Google Scholar

108. Shanley, A. Technology redefines continuous processing efficiency. Biopharm Int 2019;32:12–16.Search in Google Scholar

109. Casali, N. Escherichia coli host strains. Methods Mol Biol 2003;235:27–48. https://doi.org/10.1385/1-59259-409-3:27.10.1385/1-59259-409-3:27Search in Google Scholar PubMed

110. Sørensen, HP, Mortensen, KK. Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 2005;115:113–28. https://doi.org/10.1016/j.jbiotec.2004.08.004.Search in Google Scholar PubMed

111. Terpe, K. Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 2006;72:211–22. https://doi.org/10.1007/s00253-006-0465-8.Search in Google Scholar PubMed

112. Sanchez-Garcia, L, Martín, L, Mangues, R, Ferrer-Miralles, N, Vázquez, E, Villaverde, A. Recombinant pharmaceuticals from microbial cells: a 2015 update. Microb Cell Factories 2016;15:33. https://doi.org/10.1186/s12934-016-0437-3.Search in Google Scholar PubMed PubMed Central

113. Walsh, G. Biopharmaceutical benchmarks 2014. Nat Biotechnol 2014;32:992–1000. https://doi.org/10.1038/nbt.3040.Search in Google Scholar PubMed

114. Baeshen, NA, Baeshen, MN, Sheikh, A, Bora, RS, Ahmed, MMM, Ramadan, HAI, et al.. Cell factories for insulin production. Microb Cell Factories 2014;13:141. https://doi.org/10.1186/s12934-014-0141-0.Search in Google Scholar PubMed PubMed Central

115. Ferrer-Miralles, N, Domingo-Espín, J, Corchero, JL, Vázquez, E, Villaverde, A. Microbial factories for recombinant pharmaceuticals. Microb Cell Factories 2009;8:17. https://doi.org/10.1186/1475-2859-8-17.Search in Google Scholar PubMed PubMed Central

116. Swartz, JR. Advances in Escherichia coli production of therapeutic proteins. Curr Opin Biotechnol 2001;12:195–201. https://doi.org/10.1016/s0958-1669(00)00199-3.Search in Google Scholar PubMed

117. Tripathi, NK. Production and purification of recombinant proteins from Escherichia coli. ChemBioEng Rev 2016;3:116–33. https://doi.org/10.1002/cben.201600002.Search in Google Scholar

118. Rosano, GL, Ceccarelli, EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 2014;5:172. https://doi.org/10.3389/fmicb.2014.00172.Search in Google Scholar PubMed PubMed Central

119. Baneyx, F. Recombinant protein expression in Escherichia coli. Curr Opin Biotechnol 1999;10:411–21. https://doi.org/10.1016/s0958-1669(99)00003-8.Search in Google Scholar PubMed

120. Studier, F, Moffatt, BA. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 1986;189:113–30. https://doi.org/10.1016/0022-2836(86)90385-2.Search in Google Scholar PubMed

121. Weickert, MJ, Doherty, DH, Best, EA, Olins, PO. Optimization of heterologous protein production in Escherichia coli. Curr Opin Biotechnol 1996;7:494–9. https://doi.org/10.1016/s0958-1669(96)80051-6.Search in Google Scholar PubMed

122. Helgers, H, Hengelbrock, A, Schmidt, A, Vetter, FL, Juckers, A, Strube, J. Digital twins for scFv production in Escherichia coli. Processes 2022;10:809. https://doi.org/10.3390/pr10050809.Search in Google Scholar

123. Lau, JL, Dunn, MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem 2018;26:2700–7. https://doi.org/10.1016/j.bmc.2017.06.052.Search in Google Scholar PubMed

124. Pennington, MW, Zell, B, Bai, CJ. Commercial manufacturing of current good manufacturing practice peptides spanning the gamut from neoantigen to commercial large-scale products. Med Drug Discov 2021;9:100071. https://doi.org/10.1016/j.medidd.2020.100071.Search in Google Scholar

125. Wang, L, Wang, N, Zhang, W, Cheng, X, Yan, Z, Shao, G, et al.. Therapeutic peptides: current applications and future directions. Signal Transduct Targeted Ther 2022;7:48. https://doi.org/10.1038/s41392-022-00904-4.Search in Google Scholar PubMed PubMed Central

126. Ferrazzano, L, Catani, M, Cavazzini, A, Martelli, G, Corbisiero, D, Cantelmi, P, et al.. Sustainability in peptide chemistry: current synthesis and purification technologies and future challenges. Green Chem 2022;24:975–1020. https://doi.org/10.1039/D1GC04387K.Search in Google Scholar

127. Jadhav, S, Seufert, W, Lechner, C, Schönleber, R. Bachem – insights into innovative and sustainable peptide chemistry and technology by the leading independent manufacturer of TIDES. Chimia (Aarau) 2021;75:476–9. https://doi.org/10.2533/chimia.2021.476.Search in Google Scholar PubMed

128. Malonis, RJ, Lai, JR, Vergnolle, O. Peptide-based vaccines: current progress and future challenges. Chem Rev 2020;120:3210–29. https://doi.org/10.1021/acs.chemrev.9b00472.Search in Google Scholar PubMed PubMed Central

129. Muttenthaler, M, King, GF, Adams, DJ, Alewood, PF. Trends in peptide drug discovery. Nat Rev Drug Discov 2021;20:309–25. https://doi.org/10.1038/s41573-020-00135-8.Search in Google Scholar PubMed

130. Landgraf, W, Sandow, J. Recombinant human insulins – clinical efficacy and safety in diabetes therapy. Eur Endocrinol 2016;12:12–17. https://doi.org/10.17925/ee.2016.12.01.12.Search in Google Scholar PubMed PubMed Central

131. Sandow, J, Landgraf, W, Becker, R, Seipke, G. Equivalent recombinant human insulin preparations and their place in therapy. Eur Endocrinol 2015;11:10–16. https://doi.org/10.17925/EE.2015.11.01.10.Search in Google Scholar PubMed PubMed Central

132. Ucar, B, Acar, T, Pelit Arayici, P, Sen, M, Derman, S, Mustafaeva, Z. Synthesis and applications of synthetic peptides. In: Varkey, JT, editor. Peptide synthesis. London: IntechOpen; 2019.10.5772/intechopen.85486Search in Google Scholar

133. Sharma, A, Kumar, A, de La Torre, BG, Albericio, F. Liquid-phase peptide synthesis (LPPS): a third wave for the preparation of peptides. Chem Rev 2022;122:13516–46. https://doi.org/10.1021/acs.chemrev.2c00132.Search in Google Scholar PubMed

134. Martin, V, Egelund, PHG, Johansson, H, Le Thordal Quement, S, Wojcik, F, Sejer Pedersen, D. Greening the synthesis of peptide therapeutics: an industrial perspective. RSC Adv 2020;10:42457–92. https://doi.org/10.1039/D0RA07204D.Search in Google Scholar PubMed PubMed Central

135. Simon, MD, Heider, PL, Adamo, A, Vinogradov, AA, Mong, SK, Li, X, et al.. Rapid flow-based peptide synthesis. Chembiochem 2014;15:713–20. https://doi.org/10.1002/cbic.201300796.Search in Google Scholar PubMed PubMed Central

136. Isidro-Llobet, A, Kenworthy, MN, Mukherjee, S, Kopach, ME, Wegner, K, Gallou, F, et al.. Sustainability challenges in peptide synthesis and purification: from R&D to production. J Org Chem 2019;84:4615–28. https://doi.org/10.1021/acs.joc.8b03001.Search in Google Scholar PubMed

137. Mijalisi, AJ. Pushing the limits of solid phase peptide synthesis with continuous flow. California: UC Berkeley; 2018.10.1055/sos-SD-228-00230Search in Google Scholar

138. GMP production. https://www.bachem.com/products/services-and-capabilities/gmp-production/ [Accessed 19 Apr 2023].Search in Google Scholar

139. Custom peptide synthesis. https://www.bachem.com/products/research-and-specialties/custom-peptide-synthesis/ [Accessed 19 Apr 2023].Search in Google Scholar

140. Hessel, V, Löwe, H. Mikroverfahrenstechnik: Komponenten – Anlagenkonzeption – Anwenderakzeptanz – Teil 1. Chem Ing Tech 2002;74:17–30. https://doi.org/10.1002/1522-2640(200202)74:1/2<17:AID-CITE17>3.0.CO;2-I.10.1002/1522-2640(200202)74:1/2<17::AID-CITE17>3.3.CO;2-9Search in Google Scholar

141. Ehrfeld Mikrotechnik. Miprowa | ehrfeld mikrotechnik. https://www.ehrfeld.com/en/miprowa [Accessed 19 Apr 2023].Search in Google Scholar

142. Plutschack, MB, Pieber, B, Gilmore, K, Seeberger, PH. The Hitchhiker’s guide to flow chemistry. Chem Rev 2017;117:11796–893. https://doi.org/10.1021/acs.chemrev.7b00183.Search in Google Scholar

143. Rogers, L, Jensen, KF. Continuous manufacturing – the green chemistry promise? Green Chem 2019;21:3481–98. https://doi.org/10.1039/C9GC00773C.Search in Google Scholar

144. Bornscheuer, UT, Huisman, GW, Kazlauskas, RJ, Lutz, S, Moore, JC, Robins, K. Engineering the third wave of biocatalysis. Nature 2012;485:185–94. https://doi.org/10.1038/nature11117.Search in Google Scholar

145. Johansson, K, Frederiksen, SS, Degerman, M, Breil, MP, Mollerup, JM, Nilsson, B. Combined effects of potassium chloride and ethanol as mobile phase modulators on hydrophobic interaction and reversed-phase chromatography of three insulin variants. J Chromatogr A 2015;1381:64–73. https://doi.org/10.1016/j.chroma.2014.12.081.Search in Google Scholar

146. Zobel-Roos, S, Vetter, F, Scheps, D, Pfeiffer, M, Gunne, M, Boscheinen, O, et al.. Digital twin based design and experimental validation of a continuous peptide polishing step. Processes 2023;11:1401. https://doi.org/10.3390/pr11051401.Search in Google Scholar

147. Zobel-Roos, S, Mouellef, M, Ditz, R, Strube, J. Distinct and quantitative validation method for predictive process modelling in preparative chromatography of synthetic and bio-based feed mixtures following a quality-by-design (QbD) approach. Processes 2019;7:580. https://doi.org/10.3390/pr7090580.Search in Google Scholar

148. Zobel-Roos, S, Vetter, F, Scheps, D, Pfeiffer, M, Gunne, M, Boscheinen, O, et al.. Multivariate parameter determination of multi-component isotherms for chromatography digital twins. Processes 2023;11:1480. https://doi.org/10.3390/pr11051480.Search in Google Scholar

149. Flynn, NM, Forthal, DN, Harro, CD, Judson, FN, Mayer, KH, Para, MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654–65. https://doi.org/10.1086/428404.Search in Google Scholar

150. Hammonds, J, Chen, X, Zhang, X, Lee, F, Spearman, P. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine 2007;25:8036–48. https://doi.org/10.1016/j.vaccine.2007.09.016.Search in Google Scholar

151. Deml, L, Speth, C, Dierich, MP, Wolf, H, Wagner, R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 2005;42:259–77. https://doi.org/10.1016/j.molimm.2004.06.028.Search in Google Scholar

152. Roldão, A, Mellado, MCM, Castilho, LR, Carrondo, MJT, Alves, PM. Virus-like particles in vaccine development. Expert Rev Vaccines 2010;9:1149–76. https://doi.org/10.1586/erv.10.115.Search in Google Scholar

153. Hengelbrock, A, Helgers, H, Schmidt, A, Vetter, FL, Juckers, A, Rosengarten, JF, et al.. Digital twin for HIV-gag VLP production in HEK293 cells. Processes 2022;10:866. https://doi.org/10.3390/pr10050866.Search in Google Scholar

154. Cruz, PE, Cunha, A, Peixoto, CC, Clemente, J, Moreira, JL, Carrondo, MJ. Optimization of the production of virus-like particles in insect cells. Biotechnol Bioeng 1998;60:408–18. https://doi.org/10.1002/(sici)1097-0290(19981120)60:4<408::aid-bit2>3.0.co;2-q.10.1002/(SICI)1097-0290(19981120)60:4<408::AID-BIT2>3.3.CO;2-CSearch in Google Scholar

155. Pillay, S, Meyers, A, Williamson, A-L, Rybicki, EP. Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system. Biotechnol Prog 2009;25:1153–60. https://doi.org/10.1002/btpr.187.Search in Google Scholar

156. Puente-Massaguer, E, Grau-Garcia, P, Strobl, F, Grabherr, R, Striedner, G, Lecina, M, et al.. Accelerating HIV-1 VLP production using stable High Five insect cell pools. Biotechnol J 2021;16:e2000391. https://doi.org/10.1002/biot.202000391.Search in Google Scholar

157. Visciano, ML, Diomede, L, Tagliamonte, M, Tornesello, ML, Asti, V, Bomsel, M, et al.. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. Vaccine 2011;29:4903–12. https://doi.org/10.1016/j.vaccine.2011.05.005.Search in Google Scholar

158. Cervera, L, Gutiérrez-Granados, S, Martínez, M, Blanco, J, Gòdia, F, Segura, MM. Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium. J Biotechnol 2013;166:152–65. https://doi.org/10.1016/j.jbiotec.2013.05.001.Search in Google Scholar

159. Vickroy, B, Lorenz, K, Kelly, W. Modeling shear damage to suspended CHO cells during cross-flow filtration. Biotechnol Prog 2007;23:194–9. https://doi.org/10.1021/bp060183e.Search in Google Scholar PubMed

160. Gränicher, G, Coronel, J, Trampler, F, Jordan, I, Genzel, Y, Reichl, U. Performance of an acoustic settler versus a hollow fiber-based ATF technology for influenza virus production in perfusion. Appl Microbiol Biotechnol 2020;104:4877–88. https://doi.org/10.1007/s00253-020-10596-x.Search in Google Scholar PubMed PubMed Central

161. Voisard, D, Meuwly, F, Ruffieux, P-A, Baer, G, Kadouri, A. Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol Bioeng 2003;82:751–65. https://doi.org/10.1002/bit.10629.Search in Google Scholar PubMed

162. Cattaneo, MV, Spanjaard, RA. Perfusion filtration systems. In: U.S. Patent No. 10,358,626. 23 Jul. 2019.Search in Google Scholar

163. Patil, R, Walther, J. Continuous manufacturing of recombinant therapeutic proteins: upstream and downstream technologies. Adv Biochem Eng Biotechnol 2018;165:277–322. https://doi.org/10.1007/10_2016_58.Search in Google Scholar PubMed

164. Bielser, J-M, Wolf, M, Souquet, J, Broly, H, Morbidelli, M. Perfusion mammalian cell culture for recombinant protein manufacturing – a critical review. Biotechnol Adv 2018;36:1328–40. https://doi.org/10.1016/j.biotechadv.2018.04.011.Search in Google Scholar PubMed

165. Pereira Aguilar, P, Reiter, K, Wetter, V, Steppert, P, Maresch, D, Ling, WL, et al.. Capture and purification of Human Immunodeficiency Virus-1 virus-like particles: convective media vs porous beads. J Chromatogr A 2020;1627:461378. https://doi.org/10.1016/j.chroma.2020.461378.Search in Google Scholar PubMed

166. Floderer, C, Masson, J-B, Boilley, E, Georgeault, S, Merida, P, El Beheiry, M, et al.. Single molecule localisation microscopy reveals how HIV-1 Gag proteins sense membrane virus assembly sites in living host CD4 T cells. Sci Rep 2018;8:16283. https://doi.org/10.1038/s41598-018-34536-y.Search in Google Scholar PubMed PubMed Central

167. Cortin, V, Thibault, J, Jacob, D, Garnier, A. High-titer adenovirus vector production in 293S cell perfusion culture. Biotechnol Prog 2004;20:858–63. https://doi.org/10.1021/bp034237l.Search in Google Scholar PubMed

168. Genzel, Y, Vogel, T, Buck, J, Behrendt, I, Ramirez, DV, Schiedner, G, et al.. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells. Vaccine 2014;32:2770–81. https://doi.org/10.1016/j.vaccine.2014.02.016.Search in Google Scholar PubMed

169. Vázquez-Ramírez, D, Genzel, Y, Jordan, I, Sandig, V, Reichl, U. High-cell-density cultivations to increase MVA virus production. Vaccine 2018;36:3124–33. https://doi.org/10.1016/j.vaccine.2017.10.112.Search in Google Scholar PubMed PubMed Central

170. Vázquez-Ramírez, D, Jordan, I, Sandig, V, Genzel, Y, Reichl, U. High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system. Appl Microbiol Biotechnol 2019;103:3025–35. https://doi.org/10.1007/s00253-019-09694-2.Search in Google Scholar PubMed PubMed Central

171. Hein, MD, Chawla, A, Cattaneo, M, Kupke, SY, Genzel, Y, Reichl, U. Cell culture-based production of defective interfering influenza A virus particles in perfusion mode using an alternating tangential flow filtration system. Appl Microbiol Biotechnol 2021;105:7251–64. https://doi.org/10.1007/s00253-021-11561-y.Search in Google Scholar PubMed PubMed Central

172. Fuenmayor, J, Cervera, L, Gòdia, F, Kamen, A. Extended gene expression for Gag VLP production achieved at bioreactor scale. J Chem Tech Biotechnol 2019;94:302–8. https://doi.org/10.1002/jctb.5777.Search in Google Scholar

173. Hock, L, Poirier, M, Palasek, A, Cattaneo, MV, Spanjaard, RA, McNally, D, et al.. High-density perfusion bioreactor platform for suspension HEK293 cells. https://www.artemisbiosystems.com/wp-content/uploads/2021/02/Poster_MassBiologics_ASGCT2020.pdf [Accessed 19 Apr 2023].Search in Google Scholar

174. Shirgaonkar, IZ, Lanthier, S, Kamen, A. Acoustic cell filter: a proven cell retention technology for perfusion of animal cell cultures. Biotechnol Adv 2004;22:433–44. https://doi.org/10.1016/j.biotechadv.2004.03.003.Search in Google Scholar PubMed

175. Chotteau, V. Perfusion processes. In: Al-Rubeai, M, editor. Animal cell culture. Cham: Springer International Publishing; 2015:407–43 pp.10.1007/978-3-319-10320-4_13Search in Google Scholar

176. Coronel, J, Gränicher, G, Sandig, V, Noll, T, Genzel, Y, Reichl, U. Application of an inclined settler for cell culture-based influenza A virus production in perfusion mode. Front Bioeng Biotechnol 2020;8:672. https://doi.org/10.3389/fbioe.2020.00672.Search in Google Scholar PubMed PubMed Central

177. Helgers, H, Hengelbrock, A, Schmidt, A, Rosengarten, J, Stitz, J, Strube, J. Process design and optimization towards digital twins for HIV-gag VLP production in HEK293 cells, including purification. Processes 2022;10:419. https://doi.org/10.3390/pr10020419.Search in Google Scholar

178. Schmidt, A, Helgers, H, Vetter, FL, Juckers, A, Strube, J. Fast and flexible mRNA vaccine manufacturing as a solution to pandemic situations by adopting chemical engineering good practice—continuous autonomous operation in stainless steel equipment concepts. Processes 2021;9:1874. https://doi.org/10.3390/pr9111874.Search in Google Scholar

179. Schmidt, A, Helgers, H, Vetter, FL, Zobel-Roos, S, Hengelbrock, A, Strube, J. Process automation and control strategy by quality-by-design in total continuous mRNA manufacturing platforms. Processes 2022;10:1783. https://doi.org/10.3390/pr10091783.Search in Google Scholar

180. Vetter, FL, Zobel-Roos, S, Mota, JPB, Nilsson, B, Schmidt, A, Strube, J. Toward autonomous production of mRNA-therapeutics in the light of advanced process control and traditional control strategies for chromatography. Processes 2022;10:1868. https://doi.org/10.3390/pr10091868.Search in Google Scholar

181. Geipel-Kern, A. Covid-19-Impfstoff – warum bei den Rohstoff-Herstellern die Kasse klingelt; 2021. https://www.process.vogel.de/covid-19-impfstoff-warum-bei-den-rohstoff-herstellern-die-kasse-klingelt-a-1004361/ [Accessed 6 Mar 2021].Search in Google Scholar

182. Kis, Z, Kontoravdi, C, Shattock, R, Shah, N. Resources, production scales and time required for producing RNA vaccines for the global pandemic demand. Vaccines 2020;9. https://doi.org/10.3390/vaccines9010003.Search in Google Scholar PubMed PubMed Central

183. Rathore, AS, Thakur, G, Kateja, N. Continuous integrated manufacturing for biopharmaceuticals: a new paradigm or an empty promise? Biotechnol Bioeng 2023;120:333–51. https://doi.org/10.1002/bit.28235.Search in Google Scholar PubMed

184. Chopda, V, Gyorgypal, A, Yang, O, Singh, R, Ramachandran, R, Zhang, H, et al.. Recent advances in integrated process analytical techniques, modeling, and control strategies to enable continuous biomanufacturing of monoclonal antibodies. J Chem Tech Biotechnol 2022;97:2317–35. https://doi.org/10.1002/jctb.6765.Search in Google Scholar

185. Christensen, J. Quality issue at Baltimore vaccine plant delays some of Johnson & Johnson’s vaccine. https://edition.cnn.com/2021/03/31/health/johnson--johnson-vaccine-manufacturing-problem/index.html [Accessed 2021].Search in Google Scholar

186. Rees, V. EDQM releases new guidelines for COVID-19 vaccine quality testing. https://www.europeanpharmaceuticalreview.com/news/133928/edqm-releases-new-guidelines-for-covid-19-vaccine-quality-testing/ [Accessed 2021].Search in Google Scholar

187. Helgers, H, Hengelbrock, A, Schmidt, A, Strube, J. Digital twins for continuous mRNA production. Processes 2021;9:1967. https://doi.org/10.3390/pr9111967.Search in Google Scholar

188. Uli Beisel. BioNTainer – A manufacturing solution for Africa or circumventing capacity? Available from: https://www.medizinethnologie.net/biontainer-a-manufacturing-solution-for-africa-or-circumventing-capacity/.Search in Google Scholar

189. Saied, AA, Metwally, AA, Dhawan, M, Choudhary, OP, Aiash, H. Strengthening vaccines and medicines manufacturing capabilities in Africa: challenges and perspectives. EMBO Mol Med 2022;14:e16287. https://doi.org/10.15252/emmm.202216287.Search in Google Scholar PubMed PubMed Central

190. Wang, P, Akula, R, Chen, M, Legaspi, K. AN1616: SEC-MALS method for characterizing mRNA biophysical attributes. California: WYATT Technology; 2020.Search in Google Scholar

191. Wang, L-T, Ting, C-H, Yen, M-L, Liu, K-J, Sytwu, H-K, Wu, KK, et al.. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials. J Biomed Sci 2016;23:76. https://doi.org/10.1186/s12929-016-0289-5.Search in Google Scholar PubMed PubMed Central

192. Robb, KP, Fitzgerald, JC, Barry, F, Viswanathan, S. Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. Cytotherapy 2019;21:289–306. https://doi.org/10.1016/j.jcyt.2018.10.014.Search in Google Scholar PubMed

193. Olsen, TR, Ng, KS, Lock, LT, Ahsan, T, Rowley, JA. Peak MSC – are we there yet? Front Med 2018;5:178. https://doi.org/10.3389/fmed.2018.00178.Search in Google Scholar PubMed PubMed Central

194. Wall, IB, Brindley, DA. Commercial manufacture of cell therapies. In: Standardisation in cell and tissue engineering. Elsevier; 2013:212–39a pp.10.1533/9780857098726.2.212Search in Google Scholar

195. George, H, Freeman-Cook, L. Addressing the challenge of scalability in viral vectors. Philadelphia, PA, USA: BioprocessOnline 2021. Available from: https://www.cellandgene.com/doc/addressing-the-challenge-of-scalability-in-viral-vectors-0002.Search in Google Scholar

196. Colao, IL, Corteling, R, Bracewell, D, Wall, I. Manufacturing exosomes: a promising therapeutic platform. Trends Mol Med 2018;24:242–56. https://doi.org/10.1016/j.molmed.2018.01.006.Search in Google Scholar PubMed

197. Lenzini, S, Brennan, J, Zakhem, E, Rowley, J. Developing a microcarrier stirred tank process for large-scale hMSC-EV production; 2022. https://info.roosterbio.com/hubfs/Posters/ISEV-2022_POSTER_Developing-a-microcarrier-stirred-tank-process.pdf [Accessed 15 Feb 2023].10.1016/S1465-3249(22)00267-5Search in Google Scholar

198. Werner, S, Thompson, S, Day, R, Hawkins, B, Petrosky, J. Possibilities for continuous closed-system processing of cell therapies. Cell Gene Therapy Insights 2022;8:799–807. https://doi.org/10.18609/cgti.2022.121.Search in Google Scholar

199. Abu-Absi, S, Chan, L, Kotz, K. Application of continuous processing in cell and gene therapy: current state and future opportunities, 2019.Search in Google Scholar

200. Pigeau, GM, Csaszar, E, Dulgar-Tulloch, A. Commercial scale manufacturing of allogeneic cell therapy. Front Med 2018;5:233. https://doi.org/10.3389/fmed.2018.00233.Search in Google Scholar PubMed PubMed Central

201. NNE. Closed, automated cell therapy manufacturing – is your facility ready? https://www.nne.com/techtalk/closed-automated-cell-therapy-manufacturing/ [Accessed 20 Apr 2023].Search in Google Scholar

202. Henriette, S. Facilities for personalised medicine in the most personal form – today and tomorrow. BioPharma Asia; 2017. Available from: https://biopharma-asia.com.Search in Google Scholar

203. Lin-Gibson, S, Hanrahan, B, Matosevic, S, Jiwen Zhang, AS, Zylberberg, C. Points to consider for cell manufacturing equipment and components. Cell Gene Therapy Insights 2017;3:793–805. https://doi.org/10.18609/cgti.2017.079.Search in Google Scholar